The authors evaluated the activity of the anti-IGF-1R antibody cixutumumab with the mammalian target of rapamycin (mTOR) inhibitor temsirolimus in patients with relapsed or refractory Ewing sarcoma, osteosarcoma, rhabdomyosarcoma, and other soft tissue sarcoma, using the recommended dosages from a pediatric phase I trial.

READ FULL ARTICLE Curated publisher From Mdlinx